Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as well as the clinical efficacy and safety of alfuzosin, doxazosin (Cardura®), tamsulosin (Flomax®), and terazosin (Hytrin®) are compared. In reviewing efficacy and safety, emphasis is given to 17 placebo-controlled, double-blind trials of these alpha-blockers published in peer-reviewed journals. This review also considers long-term data, effects on blood pressure, costs, and dose ranges.

Original languageEnglish (US)
Pages (from-to)110-119
Number of pages10
JournalProstate Cancer and Prostatic Diseases
Volume2
Issue number3
StatePublished - May 1999
Externally publishedYes

Fingerprint

Terazosin
tamsulosin
Doxazosin
Prostatic Hyperplasia
Adrenergic Receptors
Safety
Placebos
Pharmacology
Blood Pressure
Costs and Cost Analysis
Therapeutics

Keywords

  • Alfuzosin
  • Benign prostatic hyperplasia
  • Doxazosin
  • Tamsulosin
  • Terazosin

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia. / Lowe, Franklin C.

In: Prostate Cancer and Prostatic Diseases, Vol. 2, No. 3, 05.1999, p. 110-119.

Research output: Contribution to journalArticle

@article{396732f0917e403cb6785c7cdaadf46b,
title = "Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia",
abstract = "In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as well as the clinical efficacy and safety of alfuzosin, doxazosin (Cardura{\circledR}), tamsulosin (Flomax{\circledR}), and terazosin (Hytrin{\circledR}) are compared. In reviewing efficacy and safety, emphasis is given to 17 placebo-controlled, double-blind trials of these alpha-blockers published in peer-reviewed journals. This review also considers long-term data, effects on blood pressure, costs, and dose ranges.",
keywords = "Alfuzosin, Benign prostatic hyperplasia, Doxazosin, Tamsulosin, Terazosin",
author = "Lowe, {Franklin C.}",
year = "1999",
month = "5",
language = "English (US)",
volume = "2",
pages = "110--119",
journal = "Prostate Cancer and Prostatic Diseases",
issn = "1365-7852",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Alpha-1-adrenoceptor blockade in the treatment of benign prostatic hyperplasia

AU - Lowe, Franklin C.

PY - 1999/5

Y1 - 1999/5

N2 - In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as well as the clinical efficacy and safety of alfuzosin, doxazosin (Cardura®), tamsulosin (Flomax®), and terazosin (Hytrin®) are compared. In reviewing efficacy and safety, emphasis is given to 17 placebo-controlled, double-blind trials of these alpha-blockers published in peer-reviewed journals. This review also considers long-term data, effects on blood pressure, costs, and dose ranges.

AB - In light of the growing interest in the concept of 'uroselectivity' and in the increased worldwide use of alpha-blockers for benign prostatic hyperplasia (BPH), this review evaluates the relative benefits of various alpha-blocking agents in the treatment of BPH. The pharmacological and physiological selectivity as well as the clinical efficacy and safety of alfuzosin, doxazosin (Cardura®), tamsulosin (Flomax®), and terazosin (Hytrin®) are compared. In reviewing efficacy and safety, emphasis is given to 17 placebo-controlled, double-blind trials of these alpha-blockers published in peer-reviewed journals. This review also considers long-term data, effects on blood pressure, costs, and dose ranges.

KW - Alfuzosin

KW - Benign prostatic hyperplasia

KW - Doxazosin

KW - Tamsulosin

KW - Terazosin

UR - http://www.scopus.com/inward/record.url?scp=0032840740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032840740&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 110

EP - 119

JO - Prostate Cancer and Prostatic Diseases

JF - Prostate Cancer and Prostatic Diseases

SN - 1365-7852

IS - 3

ER -